Abstract:BACKGROUND: Breast cancer is the most prevalent cancer among women. Doxorubicin (DOX) is a common chemotherapeutic drug used to treat many different cancers. However, multidrug resistance limits the treatment of breast cancer. MDR1 siRNA (siMDR1) combinatorial therapy has attracted significant attention as a breakthrough therapy for multidrug resistance in tumors. However, naked siRNA is easily degraded by enzymatic hydrolysis requiring an siRNA carrier for its protection. Human serum albumin (HSA) was selected as the carrier due to its excellent biocompatibility, non-toxicity, and non-immunogenicity. Cetuximab was used to modify the HSA nanoparticles in order to target the tumor tissues.METHODS: This study used a central composite design response surface methodology (CCD-RSM) to investigate the optimal formula for HSA NPs preparation. Cex-HSA/DOX/MDR1 siRNA (C-H/D/M) was characterized by dynamic light scattering and transmission electron microscopy. The efficacy of C-H/D/M tumor growth inhibitory activity was investigated in vitro and in vivo using confocal imaging, MTT assay, and an MCF-7/ADR tumor-bearing mice model. RT-qPCR, ELISA analysis, and flow cytometry were used to investigate the in vitro antitumor mechanisms of C-H/D/M.RESULTS: The diameter and PDI of the C-H/D/M were 173.57 ± 1.30 nm and 0.027 ± 0.004, respectively. C-H/D/M promoted and maintained the sustained release and the uptake of DOX significantly. After transfection, the MDR1 mRNA and P-gp expression levels were down-regulated by 44.31 ± 3.6% (P < 0.01) and 38.08 ± 2.4% (P < 0.01) in an MCF-7/ADR cell line. The fluorescent images of the treated BALB/c nude mice revealed that C-H/D/M achieved targeted delivery of siMDR1 and DOX into the tumor tissue. The in vivo tumor inhibition results demonstrated that the tumor inhibition rate of the C-H/D/M treated group was 54.05% ± 1.25%. The biosafety results indicated that C-H/D/M did not induce significant damages to the main organs in vivo.CONCLUSION: C-H/D/M can be used as an ideal non-viral tumor-targeting vector to overcome MDR and enhance the antitumor effect.

CD44-engineered Mesoporous Silica Nanoparticles for Overcoming Multidrug Resistance in Breast Cancer

Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail

Increasing The Cytotoxicity Of Doxorubicin In Breast Cancer Mcf-7 Cells With Multidrug Resistance Using A Mesoporous Silica Nanoparticle Drug Delivery System

Mesoporous Silica Nanoparticles Loading Doxorubicin Reverse Multidrug Resistance: Performance And Mechanism

Codelivery of an Optimal Drug/sirna Combination Using Mesoporous Silica Nanoparticles to Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo.

A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer

Multifunctional Aptamer-Based Nanoparticles for Targeted Drug Delivery to Circumvent Cancer Resistance

Doxorubicin and iron-doped mesoporous silica nanoparticles for chemodynamic therapy and chemotherapy of breast cancer

Multifunctional Nanosystem for Targeted and Controlled Delivery of Multiple Chemotherapeutic Agents for the Treatment of Drug-Resistant Breast Cancer

Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors

Stepwise responsive carboxymethyl chitosan-based nanoplatform for effective drug-resistant breast cancer suppression

Overcoming multidrug resistance with mesoporous silica nanorods as nanocarrier of doxorubicin.

Reductive responsive micelle overcoming multidrug resistance of breast cancer by co-delivery of DOX and specific antibiotic.

Paclitaxel and Quercetin Co-Loaded Functional Mesoporous Silica Nanoparticles Overcoming Multidrug Resistance in Breast Cancer

Synergistic Combination of Bioactive Hydroxyapatite Nanoparticles and the Chemotherapeutic Doxorubicin to Overcome Tumor Multidrug Resistance.

Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance

Doxorubicin and siRNA Co-Delivery System Based on Carbon Dots Inhibits Metastasis of Lung Cancer by Attenuating Mrp1-Mediated Resistance

Mitochondrial Targeted Doxorubicin Derivatives Delivered by ROS-responsive Nanocarriers to Breast Tumor for Overcoming of Multidrug Resistance.

Safe and Effective Reversal of Cancer Multidrug Resistance Using Sericin-Coated Mesoporous Silica Nanoparticles for Lysosome-Targeting Delivery in Mice.

Overcoming Drug Resistance with Functional Mesoporous Titanium Dioxide Nanoparticles Combining Targeting, Drug Delivery and Photodynamic Therapy

Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance